刘丽荣,文春蓉,梁璐,刘咏梅,朱丽英
LIU Lirong,WEN Chunrong,LIANG Lu,LIU Yongmei,ZHU Liying

• 1:贵州医科大学医学检验学院临床血液学教研室
• 2:贵阳市妇幼保健院检验科

摘要(Abstract)：

目的:探讨血清循环DNA(cDNA)定量检测在卵巢癌患者诊断中的应用价值。方法:以252例经病理证实的上皮性卵巢癌患者为卵巢癌组,100例卵巢良性肿瘤患者作为良性对照组,健康体检者100例作为健康对照,以微量基因组抽提试剂盒抽提3组患者血清DNA,用实时荧光定量Real-time PCR测定其含量。结果:良性对照组和健康对照组相比,血清cDNA比值差异无统计学意义(P>0.05);与良性对照组和健康对照组相比,卵巢癌组血清cDNA Ct值减少,差异有统计学意义(P<0.05);上皮性卵巢癌Ⅰ、Ⅱ、Ⅲ期血清cDNA Ct值差异无统计学意义(P>0.05),但Ⅳ期与Ⅰ期比较,差异有统计学意义(P<0.05)。结论:定量检测上皮性卵巢癌患者血清cDNA,有望成为临床辅助诊断卵巢癌的新手段。
Objective: To explore application value of quantitative detection of serum circulating DNA( cDNA) in diagnosing ovarian cancer. Methods: 252 cases of pathologically confirmed patients with epithelial ovarian cancer were enrolled as ovarian cancer group,100 cases of patients with benign ovarian cancer as benign control group,and 100 healthy people as healthy control group. Micro-genomicDNA extraction kit was adopted to extract the serum circulating DNA from the three groups and Real-time fluorescence quantitative PCR was adopted to detect the serum cDNA level. Results: There was no significantly statistical difference in level of serum cDNA between benign control group and healthy control group. There was significantly statistical difference in level of serum cDNA between ovarian cancer group and benign control group or between ovarian cancer group and healthy control group( P < 0. 05). In different clinical stage epithelial ovarian cancer,there was no difference in level of serum cDNA. Conclusion: Quantitative detection of serum cDNA of patients with ovarian cancer might be a novel auxiliary method for diagnosis of ovarian cancer.

关键词(KeyWords)： 血清学;DNA;卵巢肿瘤;诊断技术与方法
serology;DNA;ovarian cancer;diagnosis technique and method

Abstract:

Keywords:

基金项目(Foundation): 贵州省科学技术基金[黔科合J字(2011)2233号]

作者(Author): 刘丽荣,文春蓉,梁璐,刘咏梅,朱丽英
LIU Lirong,WEN Chunrong,LIANG Lu,LIU Yongmei,ZHU Liying

DOI: 10.19367/j.cnki.1000-2707.2016.05.012

参考文献(References)：

• [1]Anker P,Mulcahy H,Chen XQ,et al.Detection of circulating tumor DNA in the blood(plasma/serum)of cancer patients[J].Cancer Metastasis Rev,1999(1):65-73.
• [2]赵心亮,田广明,田亚平.人体循环游离DNA应用的研究进展[J].临床检验杂志,2013(2):109-114.
• [3]闫巍.肿瘤循环DNA的研究进展[J].实用肿瘤学杂志,2013(4):359-362.
• [4]孙朝晖,石玉玲,危敏,等.血浆循环DNA检测在鼻咽癌诊断研究中的应用[J].华南国防医学杂志,2009(3):49-51.
• [5]倪培民,孙然,王雷,等.恶性肿瘤循环DNA的研究进展[J].中国实验诊断学,2011(1):172-174.
• [6]彭亮,娄晓丽,侯彦强.循环DNA的研究进展[J].国际检验医学杂志,2013(18):2424-2426.
• [7]张世强,王保庆,王海清,等.非小细胞肺癌患者血清游离DNA定量检测的临床意义[J].山西医科大学学报,2014(10):944-946.
• [8]吴晓鸿,吴乃文,刘惜时.血清DNA定量在上皮性卵巢癌诊断中的应用研究[J].中国妇幼保健,2009(10):1413-1415.
• [9]王俊宏,潘世扬,黄佩君,等.荧光定量聚合酶链反应肺癌患者血清循环DNA的临床应用[J].中华检验医学杂志,2003(12):791.

文章评论(Comment)：